dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Borràs, Eva |
dc.contributor.author | Saiz, Albert |
dc.contributor.author | Martínez-Yélamos, Sergio |
dc.contributor.author | Pinteac, Rucsanda |
dc.contributor.author | Vidal Jordana, Angela |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Sastre Garriga, Jaume |
dc.contributor.author | Comabella Lopez, Manuel |
dc.contributor.author | Villar, Luisa M |
dc.contributor.author | Fissolo, Nicolás Miguel |
dc.date.accessioned | 2022-05-02T12:57:17Z |
dc.date.available | 2022-05-02T12:57:17Z |
dc.date.issued | 2021-11 |
dc.identifier.citation | Comabella M, Sastre-Garriga J, Borras E, Villar LM, Saiz A, Martínez-Yélamos S, et al. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Nov;8(6):e1082. |
dc.identifier.issn | 2332-7812 |
dc.identifier.uri | https://hdl.handle.net/11351/7442 |
dc.description | Esclerosi múltiple; Quitinasa |
dc.description.sponsorship | This work was funded by grants from the International Progressive MS Alliance (grant no. PA0020), Asociación Esclerosis Múltiple (EME)—Red Española de Esclerosi múltiple (REEM), REEM (RD16/0015/002 and RD16/0015/003) cofunded by the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER, Otra manera de hacer Europa). |
dc.language.iso | eng |
dc.publisher | Lippincott Williams & Wilkins |
dc.relation.ispartofseries | Neurology - Neuroimmunology & Neuroinflammation;8(6) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Glicosidases |
dc.subject | Esclerosi múltiple - Prognosi |
dc.subject.mesh | Multiple Sclerosis, Chronic Progressive |
dc.subject.mesh | Chitinases |
dc.subject.mesh | Disease Progression |
dc.title | CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/NXI.0000000000001082 |
dc.subject.decs | esclerosis múltiple crónica progresiva |
dc.subject.decs | quitinasas |
dc.subject.decs | progresión de la enfermedad |
dc.relation.publishversion | https://doi.org/10.1212/NXI.0000000000001082 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Comabella M, Sastre-Garriga J, Pinteac R, Fissolo N, Vidal-Jordana A, Montalban X] Unitat de Neuroimmunologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borras E] Proteomics Unit, Universitat Pompeu Fabra, Barcelona. [Villar LM] Departments of Neurology and Immunology, Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid. [Saiz A] Service of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi Sunyer, University of Barcelona. [Martínez-Yélamos S] Department of Neurology, Bellvitge University Hospital, Barcelona |
dc.identifier.pmid | 34497102 |
dc.identifier.wos | 000712132000035 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |